A 2014 study in European Radiology showed that the algorithm generated high accuracy, nearing 100%, with a corresponding low rate of false-positive detections for lung nodules 4 mm and larger and fewer than two false-positives per case.

The technology was originally geared toward lung cancer screening, but it has been refined to make it suitable for general chest CT scans and also to adhere to current lung cancer screening protocols, the company said.

The platform is now operational in a few clinical sites, including El Camino Hospital in Mountain View, CA, where it is used daily for chest CT studies, according to RadLogics.